Page last updated: 2024-11-04

sulfamethoxypyridazine and Benign Neoplasms

sulfamethoxypyridazine has been researched along with Benign Neoplasms in 1 studies

Sulfamethoxypyridazine: A sulfanilamide antibacterial agent.
sulfamethoxypyridazine : A sulfonamide consisting of pyridazine having a methoxy substituent at the 6-position and a 4-aminobenzenesulfonamido group at the 3-position.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lin, R1
Elf, S1
Shan, C1
Kang, HB1
Ji, Q1
Zhou, L1
Hitosugi, T1
Zhang, L1
Zhang, S1
Seo, JH1
Xie, J1
Tucker, M1
Gu, TL1
Sudderth, J1
Jiang, L1
Mitsche, M1
DeBerardinis, RJ1
Wu, S1
Li, Y1
Mao, H1
Chen, PR1
Wang, D1
Chen, GZ1
Hurwitz, SJ1
Lonial, S1
Arellano, ML1
Khoury, HJ1
Khuri, FR1
Lee, BH1
Lei, Q1
Brat, DJ1
Ye, K1
Boggon, TJ1
He, C1
Kang, S1
Fan, J1
Chen, J1

Reviews

1 review available for sulfamethoxypyridazine and Benign Neoplasms

ArticleYear
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
    Nature cell biology, 2015, Volume: 17, Issue:11

    Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms;

2015